Inhaled human insulin

Nature Reviews Drug Discovery

Volumn 5, Issue 5, 2006, Pages 371-372

  Owens, David R ^a   Grimley, Joanne ^b   Kirkpatrick, Peter ^c  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

AERX INSULIN SYSTEM; AIR INSULIN; HUMAN INSULIN; HUMULIN U ULTRALENTE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING DRUG; ROSIGLITAZONE; SHORT ACTING DRUG; TECHNOSPHERE INSULIN SYSTEM;

ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG PACKAGING; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRY POWDER; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG TOXICITY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; WEIGHT GAIN;

ADMINISTRATION, INHALATION; ADULT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS;

EID: 33745205863     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2052     Document Type: Article

References (17)

1. Leahy, J. L. & Cefalu, W. T. (eds). Insulin Therapy (Marcel Dekker, New York, 2002).
2. Owens, D. R. New horizons - alternative routes for insulin therapy. Nature Rev. Drug Discov. 1, 529-540 (2002).
3. White, S. et al. Exubera: Pharmaceutical development of novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 7, 896-906 (2005).
4. Quattrin, T. et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27, 2622-2627 (2004).
5. FDA labelling information [online], (2006).
6. DeFronzo, R. A. et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial. Diabetes Care 27, 1922-1928 (2005).
7. Hollander, P. A. et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27, 2356-2362 (2004).
8. CHMP summary of opinion [online], (2005).
9. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287, 2563-2569 (2002).
10. Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321, 405-412 (2000).
11. Saunders, S. A. et al. Glycaemic control in a type 1 diabetes clinic for younger adults. QJM 97, 575-580 (2004).
12. Brown, J. B. et al. The burden of treatment failure in type 2 diabetes. Diabetes Care 27, 1535-1540 (2004).
13. Peyrot, M. et al. Resistance to insulin therapy among patients and providers. Diabetes Care 28, 2673-2679, (2005).
14. Rosenstock, J. et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27, 1318-1323 (2004).
15. International Diabetes Federation, .
16. WHO, .
17. IMS Health, IMS MIDAS Quantum, MAT (Dec 2005).